ClinicalTrials.gg
CompletedNCT04402125TEAM2Updated Oct 28, 2026Results posted

Reducing Stroke Risk in African-American Men

An interventional study of TargEted MAnageMent Intervention (TEAM) in Stroke and Transient Ischemic Attack, sponsored by Case Western Reserve University. Completed at 1 site in United States. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Case Western Reserve University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.

Enrollment
293rd of 1,621
171 · median 40
Started
2020
with 87 others
No phase
1,124 of 1,995
270 open now
Registered
1,284th of 1,995
by date

Among the 1,995 studies in Stroke with a site in United States, this one is the 293rd largest by enrollment of the 1,621 interventional ones that give a count, is one of 88 that started in 2020, is one of 1,124 with no phase, and was the 1,284th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:

387 more — sign in →

All 392 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,995 studies in Stroke with a site in United States, or all of them as a file.
02

Study summary

The project is a 6-month prospective Randomized Controlled Trial evaluating the effects of TargEted MAnageMent Intervention (TEAM, N=80) vs. wait-list (WL, N=80) control in African American men who have experienced a stroke or TIA within the past 5 years.

Read the detailed description

The project is a 6-month prospective Randomized Controlled Trial evaluating the effects of TargEted MAnageMent Intervention (TEAM, N=80) vs. wait-list (WL, N=80) control in African American men who have experienced a stroke or TIA within the past 5 years. TEAM features a nurse-led, person-centered, holistic intervention that takes advantage of existing strengths in AA families/communities. TEAM uses peer educator dyads (PEDs) to provide support and model behaviors. The PED consists of an AA man peer educator (PE) with experience in managing his own stroke risk and a care partner. A care partner is someone who is the family member, friend or other individual of someone who has had a stroke or TIA. A care partner can be associated with a PE but they do not have to be. PEs and care partners will be matched depending on schedules and availability and may not always be members of the same household. The nurse and PED co-deliver TEAM to an AA male patient who has experienced stroke or TIA. Patients are also encouraged to include a family, friend, or other individual important his stroke recovery in the TEAM programming. The intervention is a practical approach suitable for implementation in specialty, primary care or community settings, and has the potential to reverse the unacceptably high morbidity seen in AA men due to stroke-related disorders.

03

Conditions studied

  • Stroke
  • Transient Ischemic Attack
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for RCT participant:

  1. Age range 18 to 90
  2. Self-identified African American male
  3. Have had a stroke or in the past 10 years based on date of hospital discharge from an acute stroke program or Emergency Room/physician visit for TIA
  4. Barthel Index (BI) score of >= 40
  5. Able to participate in group sessions

Inclusion Criteria for Care Partner

  1. Age range from 18 to 90
  2. Able to participate in group sessions

Inclusion criteria for peer educator:

  1. Age range: from 18 to 90
  2. Self-identified African American male
  3. Have had a stroke or TIA
  4. Able to participate in group sessions

Inclusion Criteria for Peer Educator Care Partner

  1. Age range: from 18 to 90
  2. Able to participate in group sessions
  3. Is either a family member, friend or other individual who is important in an enrolled peer educator's stroke recovery OR the family member, friend or other individual of someone who has had a stroke or TIA and is/was important in their stroke recovery

Exclusion Criteria for RCT participant

  1. Individuals who are unable or unwilling to provide written
  2. Individuals who have had stroke due to sickle-cell disease

Exclusion Criteria for Care Partner participant 1. Individuals who are unable or unwilling to provide written informed consent

Exclusion Criteria for Peer Educator

  1. Individuals who are unable or unwilling to provide written informed consent
  2. Individuals who have had stroke due to sickle-cell disease

Exclusion Criteria for Peer Educator's Care Partner

1. Individuals who are unable or unwilling to provide written informed consent

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Intervention

    Participants randomized to TEAM intervention for 6 months, then observed for 6 month follow up

    Behavioral: TargEted MAnageMent Intervention (TEAM)

  • Other
    Waitlist

    Participants randomized to waitlist for 6 months, then offered the intervention for 6 months

    Behavioral: TargEted MAnageMent Intervention (TEAM)

Interventions

  • BehavioralTargEted MAnageMent Intervention (TEAM)

    TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows: 1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning. 2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED. 3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers.

06

What researchers measure

Primary outcomes

  1. TEAM vs WL Systolic BP

    BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.

    Time frame: Baseline, Month 3, Month 6

Secondary outcomes

  1. TEAM vs WL Diastolic BP

    BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.

    Time frame: Baseline, Month 3, Month 6

  2. TEAM vs WL Cholesterol

    Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

    Time frame: Baseline, Month 6

  3. TEAM vs WL HDL

    Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

    Time frame: Baseline, Month 6

  4. TEAM vs WL LDL

    Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

    Time frame: Baseline, Month 6

  5. TEAM vs WL Triglycerides

    Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

    Time frame: Baseline, Month 6

  6. TEAM vs WL BMI

    Height was measured at baseline and weight was measured at baseline and at 6-month follow-up timepoints. If individuals were unable to provide accurate height and weight measurements, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

    Time frame: Baseline, Month 6

  7. TEAM vs WL HbA1c

    Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

    Time frame: Baseline, Month 6

Other outcomes

  1. TEAM vs WL Stroke Knowledge Test (SKT)

    The SKT is a 20-item multiple-choice test designed to measure knowledge and understanding of stroke, stroke risk, stroke risk factors, and stroke prevention practices. In this study, only five specific questions were asked to examine each participant's knowledge of specific stroke risk factors and stroke prevention practices. Possible scores range for 0-5, with a higher score indicating a higher amount of knowledge and understanding

    Time frame: Baseline, Month 3, Month 6

  2. TEAM vs WL General Self-Efficacy Scale (GSE)

    The GSE a 10-item psychological questionnaire designed to measure an individual's optimistic self-belief in their ability to handle difficult demands, cope with stress, and overcome obstacles. Total scores range from 10 to 40, where higher scores mean a stronger general sense of self-efficacy

    Time frame: Baseline, Month 3, Month 6

  3. TEAM vs. WL Medical Outcomes Study Social Support Survey (MOS-SS)

    The MOS-SS is a 19-item, self-administered questionnaire designed to measure the perceived availability of functional social support. Scores are transformed to a 0-100 scale, where higher scores mean more available support

    Time frame: Baseline, Month 3, Month 6

  4. TEAM vs WL Number of Stroke Risk Medications

    The measure represents the number of medications a participant was taken to lower their risk of having another stroke

    Time frame: Baseline, Month 3, Month 6

  5. TEAM vs. WL Tablet Routine Questionnaire (TRQ)

    The TRQ item is a subject report of the percentage of prescribed medications due reduce stroke risk not taken within the past week.

    Time frame: Baseline, Month 3, Month 6

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneInterventionWaitlistPeer EducatorsPeer Educator Care Partner
Started788274
Completed676654
Not completed111620

Outcome measures

PrimaryTEAM vs WL Systolic BP

BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · mmHg
TEAM vs WL Systolic BP
mmHgTotal ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline136.17 ± 1.17136.06 ± 2.34136.28 ± 2.22——
Month 3135.04 ± 1.95137.15 ± 2.8132.93 ± 2.71——
Month 6133.58 ± 1.77133.71 ± 2.55133.44 ± 2.45——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = 0.52 (Within-time main effects for entire sample p-values)
SecondaryTEAM vs WL Diastolic BP

BP was assessed using an Omron 3 Model BP7100 (Omron Healthcare, 2018). As RCT enrollment began shortly before the onset of the COVID-19 pandemic, BP assessments were primarily done remotely, using home-based BP evaluation methods. In situations where individuals were unable to capture BP readings using multiple home-based measurements, the baseline BP data could be obtained using either homebased reading, an in-person BP reading conducted by the study team or clinical research unit nursing staff or extracted from the electronic health record up to 8 weeks prior to or 6 weeks after the baseline time-point and up to 6 weeks before or after follow-up time points. The team prioritized home-based or in-person BP measurement capture and only used electronic health record extraction if other methods of BP evaluation were not available.

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · mmHg
TEAM vs WL Diastolic BP
mmHgTotal ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline82.48 ± 1.1082.61 ± 1.5982.35 ± 1.51——
Month 380.51 ± 1.1081.56 ± 1.5879.46 ± 1.53——
Month 681.19 ± 1.0681.10 ± 1.5381.27 ± 1.47——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = 0.28 (Within-time main effects for entire sample p-values)
SecondaryTEAM vs WL Cholesterol

Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

Time frame:
Baseline, Month 6
Reported as:
Mean · mg/dL
TEAM vs WL Cholesterol
mg/dLTotal ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline146.83 ± 7.34151.19 ± 9.82142.48 ± 10.92——
Month 6144.53 ± 5.72148.92 ± 7.65140.14 ± 8.51——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = 0.69 (Within-time main effects for entire sample p-values)
SecondaryTEAM vs WL HDL

Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

Time frame:
Baseline, Month 6
Reported as:
Mean · mg/dL
TEAM vs WL HDL
mg/dLTotal ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline45.68 ± 1.8642.62 ± 2.5248.75 ± 2.74——
Month 646.14 ± 1.8744.51 ± 2.5347.76 ± 2.75——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = 0.78 (Within-time main effects for entire sample p-values)
SecondaryTEAM vs WL LDL

Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

Time frame:
Baseline, Month 6
Reported as:
Mean · mg/dL
TEAM vs WL LDL
mg/dLTotal ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline80.64 ± 5.8482.88 ± 8.0878.41 ± 8.44——
Month 680.86 ± 4.4683.08 ± 6.1878.64 ± 6.45——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = 0.96 (Within-time main effects for entire sample p-values)
SecondaryTEAM vs WL Triglycerides

Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

Time frame:
Baseline, Month 6
Reported as:
Mean · mg/dL
TEAM vs WL Triglycerides
mg/dLTotal ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline118.17 ± 15.04132.04 ± 20.05104.3 ± 22.42——
Month 6113.25 ± 16.19137.8 ± 21.5888.70 ± 24.13——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = 0.69 (Within-time main effects for entire sample p-values)
SecondaryTEAM vs WL BMI

Height was measured at baseline and weight was measured at baseline and at 6-month follow-up timepoints. If individuals were unable to provide accurate height and weight measurements, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

Time frame:
Baseline, Month 6
Reported as:
Mean · kg/m²
TEAM vs WL BMI
kg/m²Total ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline30.58 ± 0.7431.82 ± 1.0229.34 ± 1.06——
Month 630.19 ± 0.7531.48 ± 1.0528.89 ± 1.09——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = 0.13 (Within-time main effects for entire sample p-values.)
SecondaryTEAM vs WL HbA1c

Laboratory testing for serum total cholesterol, HDL, LDL, triglycerides, and HbA1c was conducted at baseline and at 6-month follow-up timepoints. Laboratory testing was conducted using an academic medical center clinical services or national laboratory services for participants who resided outside of the regional reach of the medical center. If individuals were unable to travel to laboratory testing locations due to the COVID-19 pandemic restrictions, results were extracted from the electronic health record using similar timeframes as the BP health record data extraction.

Time frame:
Baseline, Month 6
Reported as:
Mean · percentage of glycosylated hemoglobin
TEAM vs WL HbA1c
percentage of glycosylated hemoglobinTotal ParticipantsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline7.63 ± 0.187.93 ± 0.277.34 ± 0.25——
Month 67.31 ± 0.227.24 ± 0.327.40 ± 0.30——
Statistical analysis
  • Total Participants vs Intervention vs Waitlist · Repeated Measures Mixed Model Analysis · p = <.05 (Within-Time × Group interaction effects p-values)
Other pre-specifiedTEAM vs WL Stroke Knowledge Test (SKT)

The SKT is a 20-item multiple-choice test designed to measure knowledge and understanding of stroke, stroke risk, stroke risk factors, and stroke prevention practices. In this study, only five specific questions were asked to examine each participant's knowledge of specific stroke risk factors and stroke prevention practices. Possible scores range for 0-5, with a higher score indicating a higher amount of knowledge and understanding

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · units on a scale
TEAM vs WL Stroke Knowledge Test (SKT)
units on a scaleInterventionWaitlistPeer EducatorPeer Educator Care Partners
Baseline3.98 ± 0.184.35 ± 0.18——
Month 34.50 ± 0.184.28 ± 0.19——
Month 64.32 ± 0.154.67 ± 0.15——
Other pre-specifiedTEAM vs WL General Self-Efficacy Scale (GSE)

The GSE a 10-item psychological questionnaire designed to measure an individual's optimistic self-belief in their ability to handle difficult demands, cope with stress, and overcome obstacles. Total scores range from 10 to 40, where higher scores mean a stronger general sense of self-efficacy

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · units on a scale
TEAM vs WL General Self-Efficacy Scale (GSE)
units on a scaleInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline34.02 ± 0.7832.72 ± 0.78——
Month 332.37 ± 0.9932.66 ± 1.00——
Month 632.13 ± 1.0032.67 ± 0.99——
Other pre-specifiedTEAM vs. WL Medical Outcomes Study Social Support Survey (MOS-SS)

The MOS-SS is a 19-item, self-administered questionnaire designed to measure the perceived availability of functional social support. Scores are transformed to a 0-100 scale, where higher scores mean more available support

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · units on a scale
TEAM vs. WL Medical Outcomes Study Social Support Survey (MOS-SS)
units on a scaleInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline72.00 ± 4.6973.40 ± 4.55——
Month 367.82 ± 5.4368.50 ± 5.43——
Month 667.70 ± 5.3766.52 ± 5.28——
Other pre-specifiedTEAM vs WL Number of Stroke Risk Medications

The measure represents the number of medications a participant was taken to lower their risk of having another stroke

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · number of medications
TEAM vs WL Number of Stroke Risk Medications
number of medicationsInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline3.02 ± 0.342.63 ± 0.35——
Month 32.75 ± 0.353.2 ± 0.37——
Month 62.74 ± 0.332.71 ± 0.35——
Other pre-specifiedTEAM vs. WL Tablet Routine Questionnaire (TRQ)

The TRQ item is a subject report of the percentage of prescribed medications due reduce stroke risk not taken within the past week.

Time frame:
Baseline, Month 3, Month 6
Reported as:
Mean · percentage of doses missed
TEAM vs. WL Tablet Routine Questionnaire (TRQ)
percentage of doses missedInterventionWaitlistPeer EducatorsPeer Educator Care Partners
Baseline4.7 ± 3.4513.76 ± 3.33——
Month 36.00 ± 3.7213.70 ± 3.56——
Month 65.82 ± 3.9911.63 ± 3.81——

Adverse events

Collected over From enrollment until end of follow-up, up to 12 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention0/160 (0%)4/160 (2.5%)2/160 (1.3%)
Observation0/160 (0%)14/160 (8.8%)10/160 (6.3%)
Peer Educators0/7 (0%)0/7 (0%)0/7 (0%)
Peer Educator Care Partners0/4 (0%)0/4 (0%)0/4 (0%)
Most frequent serious events
Most frequent serious events
EventInterventionObservationPeer EducatorsPeer Educator Care Partners
Hospitalization due to underlying medical conditionsGeneral disorders4/16012/1600/70/4
Hospitalization due to unknown reasonsGeneral disorders0/1604/1600/70/4
Hospitalization due to combined medical and psychological conditionsGeneral disorders0/1602/1600/70/4
Hospitalization due to psychological conditions (psychiatric or substance use problems)Psychiatric disorders0/1601/1600/70/4
Most frequent other events
Showing 10 of 12
Most frequent other events
EventInterventionObservationPeer EducatorsPeer Educator Care Partners
FallGeneral disorders2/1600/1600/70/4
Leg injuryGeneral disorders0/1601/1600/70/4
Alcohol intoxicationPsychiatric disorders0/1601/1600/70/4
Abdominal painGeneral disorders0/1601/1600/70/4
Eye PainEye disorders0/1601/1600/70/4
Toe painGeneral disorders0/1601/1600/70/4
Drug overdosePsychiatric disorders0/1601/1600/70/4
HematomaVascular disorders0/1601/1600/70/4
High Blood PressureCardiac disorders0/1601/1600/70/4
EnteritisGeneral disorders0/1601/1600/70/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
Mean61.3 ± 9.261.1 ± 9.859.6 ± 15.144.5 ± 20.561.2 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
Female00044
Male788270167
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
American Indian or Alaska Native000—0
Asian000—0
Native Hawaiian or Other Pacific Islander000—0
Black or African American78827—167
White000—0
More than one race000—0
Unknown or Not Reported000—0
Lives Alone
Lives Alone(participants)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
Number26292—57
Education
Education(years)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
Mean14.2 ± 2.313.8 ± 2.1——14.0 ± 2.2
Average systolic blood pressure
Average systolic blood pressure(mmHg)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
Mean135.7 ± 18.4135.0 ± 17.5——135.3 ± 17.9
Average diastolic blood pressure
Average diastolic blood pressure(mmHg)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
Mean83.6 ± 10.782.4 ± 13.1——83.0 ± 12.0
BMI
BMI(kg/m²)InterventionWaitlistPeer EducatorPeer Educator Care PartnersTotal
Mean31.0 ± 6.929.1 ± 5.3——30.1 ± 6.2

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
09

References and documents

Publications

  • Still CH, Burant C, Moore S, Einstadter D, Killion C, Modlin C, Sundararajan S, Thornton JD, Wright JT Jr, Sajatovic M. The Targeted Management (TEAM) Intervention for Reducing Stroke Risk in African American Men: Rationale and Study Design of a Prospective Randomized Controlled Trial. J Multidiscip Healthc. 2021 Feb 23;14:513-522. doi: 10.2147/JMDH.S288753. eCollection 2021. PubMed 33654407 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Sep 2025, 64 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 64 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2020
First posted
May 26, 2020
StartActual
May 5, 2020
Primary completionActual
Sep 8, 2025
CompletionActual
Sep 8, 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Enrollment
160→171
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTEAM vs WL change in systolicSystolic BPTime frame: Baseline to 6-month follow up → Baseline, Month 3, Month 6
Oct 28, 2026
Documents
Secondary outcomes
7 edited, 5 added
What changed in the outcomes
  • EditedTEAM vs WL change in diastolicDiastolic BPTime frame: Baseline to 6-month follow up → Baseline, Month 3, Month 6
  • EditedTEAM vs WL change in cholesterolCholesterolTime frame: Baseline to 6-month follow up → Baseline, Month 6
  • EditedTEAM vs WL change in HDLTime frame: Baseline to 6-month follow up → Baseline, Month 6
  • EditedTEAM vs WL change in LDLTime frame: Baseline to 6-month follow up → Baseline, Month 6
  • EditedTEAM vs WL change in triglyceridesTriglyceridesTime frame: Baseline to 6-month follow up → Baseline, Month 6
  • EditedTEAM vs WL change in BMITime frame: Baseline to 6-month follow up → Baseline, Month 6
  • EditedTEAM vs WL change in HbA1cTime frame: Baseline to 6-month follow up → Baseline, Month 6
  • Addedother outcomeTEAM vs WL Stroke Knowledge Test (SKT)Time frame: Baseline, Month 3, Month 6
  • Addedother outcomeTEAM vs WL General Self-Efficacy Scale (GSE)Time frame: Baseline, Month 3, Month 6
  • Addedother outcomeTEAM vs. WL Medical Outcomes Study Social Support Survey (MOS-SS)Time frame: Baseline, Month 3, Month 6
  • Addedother outcomeTEAM vs WL Number of Stroke Risk MedicationsTime frame: Baseline, Month 3, Month 6
  • Addedother outcomeTEAM vs. WL Tablet Routine Questionnaire (TRQ)Time frame: Baseline, Month 3, Month 6
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Enrollment 160→171
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTEAM vs WL change in systolicSystolic BPTime frame: Baseline to 6-month follow up → Baseline, Month 3, Month 6
    Secondary outcomes 7 edited, 5 added
    What changed in the outcomes
    • EditedTEAM vs WL change in diastolicDiastolic BPTime frame: Baseline to 6-month follow up → Baseline, Month 3, Month 6
    • EditedTEAM vs WL change in cholesterolCholesterolTime frame: Baseline to 6-month follow up → Baseline, Month 6
    • EditedTEAM vs WL change in HDLTime frame: Baseline to 6-month follow up → Baseline, Month 6
    • EditedTEAM vs WL change in LDLTime frame: Baseline to 6-month follow up → Baseline, Month 6
    • EditedTEAM vs WL change in triglyceridesTriglyceridesTime frame: Baseline to 6-month follow up → Baseline, Month 6
    • EditedTEAM vs WL change in BMITime frame: Baseline to 6-month follow up → Baseline, Month 6
    • EditedTEAM vs WL change in HbA1cTime frame: Baseline to 6-month follow up → Baseline, Month 6
    • Addedother outcomeTEAM vs WL Stroke Knowledge Test (SKT)Time frame: Baseline, Month 3, Month 6
    • Addedother outcomeTEAM vs WL General Self-Efficacy Scale (GSE)Time frame: Baseline, Month 3, Month 6
    • Addedother outcomeTEAM vs. WL Medical Outcomes Study Social Support Survey (MOS-SS)Time frame: Baseline, Month 3, Month 6
    • Addedother outcomeTEAM vs WL Number of Stroke Risk MedicationsTime frame: Baseline, Month 3, Month 6
    • Addedother outcomeTEAM vs. WL Tablet Routine Questionnaire (TRQ)Time frame: Baseline, Month 3, Month 6
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04402125
Responsible party
Martha Sajatovic, MD (Professor, Case Western Reserve University) — Principal investigator
First posted
May 26, 2020
Start date
May 5, 2020
Primary completion
Sep 8, 2025
Completion
Sep 8, 2025
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Martha Sajatovic, MD
principal investigator · Case Western Reserve University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion